Toresson L, Steiner J M, Razdan P, Spodsberg E, Olmedal G, Suchodolski J S, Spillmann T
Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, Helsinki University, Agnes Sjobergin katu 2, 00014 Helsinki, Finland; Evidensia Specialist Animal Hospital, Bergavagen 3, 25466 Helsingborg, Sweden.
Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, Texas A&M University, 4474 TAMU, College Station, TX 77843-4474, USA.
Vet J. 2018 Feb;232:27-32. doi: 10.1016/j.tvjl.2017.12.010. Epub 2017 Dec 13.
The aim of this study was to compare the efficacies of parenteral and oral cobalamin supplementation protocols in dogs with chronic enteropathies and low cobalamin concentrations. It was hypothesised that both treatments would increase serum cobalamin concentrations significantly. Fifty-three dogs with chronic enteropathies and serum cobalamin concentrations<285ng/L (reference interval 244-959ng/L) were enrolled. Dogs were randomised to treatment with either daily oral cobalamin tablets (0.25-1.0mg cyanocobalamin daily according to body weight) or parenteral cobalamin (0.4-1.2mg hydroxycobalamin according to body weight). Serum cobalamin concentrations were analysed 28±5days and 90±15days after initiation of supplementation. After 28 days, all dogs had serum cobalamin concentrations within the reference interval or above. In the parenteral group (n=26), median (range) cobalamin concentrations were 228 (150-285) ng/L at inclusion, 2107 (725-10,009) ng/L after 28days and 877 (188-1267) ng/L after 90 days. In the oral group (n=27), median (range) serum cobalamin concentrations were 245 (150-285) ng/L at inclusion, 975 (564-2385) ng/L after 28days and 1244 (738-4999) ng/L after 90 days. In both groups, there were significant differences in serum cobalamin concentrations between baseline and 28 days, and between 28days and 90days (P<0.001). In conclusion, both parenteral and oral cobalamin supplementation effectively increase serum cobalamin concentrations in dogs with chronic enteropathies and low cobalamin concentrations.
本研究的目的是比较肠胃外和口服钴胺素补充方案对患有慢性肠病且钴胺素浓度较低的犬类的疗效。研究假设两种治疗方法均能显著提高血清钴胺素浓度。纳入了53只患有慢性肠病且血清钴胺素浓度<285ng/L(参考区间为244 - 959ng/L)的犬。犬被随机分为两组,一组每日口服钴胺素片(根据体重每日服用0.25 - 1.0mg氰钴胺素),另一组进行肠胃外钴胺素治疗(根据体重注射0.4 - 1.2mg羟基钴胺素)。在开始补充后28±5天和90±15天分析血清钴胺素浓度。28天后,所有犬的血清钴胺素浓度均在参考区间内或高于参考区间。肠胃外治疗组(n = 26),纳入时钴胺素浓度中位数(范围)为228(150 - 285)ng/L,28天后为2107(725 - 10,009)ng/L,90天后为877(188 - 1267)ng/L。口服组(n = 27),纳入时血清钴胺素浓度中位数(范围)为245(150 - 285)ng/L,28天后为975(564 - 2385)ng/L,90天后为1244(738 - 4999)ng/L。两组中,基线与28天之间以及28天与90天之间血清钴胺素浓度均存在显著差异(P<0.001)。总之,肠胃外和口服钴胺素补充均能有效提高患有慢性肠病且钴胺素浓度较低的犬的血清钴胺素浓度。